Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more
Arcturus Therapeutics Holdings Inc (ARCT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.076x
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) has a cash flow conversion efficiency ratio of -0.076x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.23 Million) by net assets ($213.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arcturus Therapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arcturus Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcturus Therapeutics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Savior Lifetec
TWO:4167
|
0.028x |
|
Sunny Friend Environmental Technology Co Ltd
TW:8341
|
0.039x |
|
Advanced Process Systems Corporation
KQ:265520
|
0.038x |
|
WEYCO GRP INC. DL 1
F:WY1
|
N/A |
|
PT Bangun Kosambi Sukses Tbk
JK:CBDK
|
0.019x |
|
Baoding Dongli Machinery Co.Ltd.
SHE:301298
|
N/A |
|
Zhejiang Taifu Pump Co. Ltd
SHE:300992
|
0.101x |
|
Ressources Minieres Radisson Inc
V:RDS
|
0.013x |
Annual Cash Flow Conversion Efficiency for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Arcturus Therapeutics Holdings Inc from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $213.99 Million | $-74.27 Million | -0.347x | -39.99% |
| 2024-12-31 | $240.98 Million | $-59.75 Million | -0.248x | -281.53% |
| 2023-12-31 | $278.51 Million | $-18.10 Million | -0.065x | -154.91% |
| 2022-12-31 | $270.31 Million | $31.99 Million | 0.118x | +120.00% |
| 2021-12-31 | $228.21 Million | $-135.04 Million | -0.592x | -447.49% |
| 2020-12-31 | $396.55 Million | $-42.86 Million | -0.108x | +56.75% |
| 2019-12-31 | $25.79 Million | $-6.45 Million | -0.250x | +83.58% |
| 2018-12-31 | $13.64 Million | $-20.76 Million | -1.522x | -11079.72% |
| 2017-12-31 | $33.79 Million | $-460.00K | -0.014x | +96.66% |
| 2016-12-31 | $47.23 Million | $-19.24 Million | -0.407x | -55.64% |
| 2015-12-31 | $69.33 Million | $-18.15 Million | -0.262x | +81.57% |
| 2014-12-31 | $19.94 Million | $-28.33 Million | -1.420x | -840.49% |
| 2013-12-31 | $48.69 Million | $-7.35 Million | -0.151x | -105.40% |
| 2012-12-31 | $-567.00K | $-1.58 Million | 2.795x | +216.62% |
| 2011-12-31 | $985.00K | $-2.36 Million | -2.397x | -- |